Ulcerative colitis

Recent Findings on ulcerative colitis

• A phase 2b, randomised, placebo-controlled RELIEVE UCCD trial investigated duvakitug, an anti-TNF-like cytokine 1A (TL1A) monoclonal antibody, in adults with moderately to severely active UC. The study was designed to evaluate the drug’s efficacy and safety, placing TL1A-directed therapy within the broader development of targeted treatments for inflammatory bowel diseases 42462750Jul.

• A study of Banqiao Codonopsis Radix polysaccharides examined ultrasound-assisted extraction, including process optimisation, extraction mechanisms, and in vivo efficacy in ulcerative colitis. The extracted polysaccharides showed anti-UC effects comparable to those of conventionally prepared polysaccharides in the reported experimental model. The proposed mechanisms included regulation of the gut microbiota, modulation of serum corticosterone metabolism, and inhibition of the cytokine–cytokine receptor interaction pathway 42546441Aug. This work extends the literature theme of polysaccharide immunomodulation in colitis.

• Chishizhi Yuyuliang Decoction was investigated in mice with experimental UC using integrated metabolomics and proteomics. The study focused on whether the treatment promotes colonic epithelial mucosal healing through the CAV1/FA axis, combining molecular profiling with assessment of therapeutic mechanisms 42200545May. Its emphasis on epithelial repair complements research focused primarily on inflammatory cytokines such as IL-6 and IL-1β.

• Fufang Tongye Shaoshang You was evaluated in DSS-induced colitis in mice. The reported therapeutic framework combined inhibition of inflammation, regulation of the microbiota, and protection of the mucosa. UC-associated targets were identified through analysis of GEO transcriptomic datasets, supporting a systems-level approach to linking treatment effects with inflammatory and barrier-related mechanisms 41997437Apr.

• Self-assembled nanoparticles derived from Rubia cordifolia L. were studied before and after carbonization as potential targeted treatments for UC. Mice with DSS-induced colitis received either R. cordifolia nanoparticles or nanoparticles prepared after carbonization at doses of 1.3 or 5.2 g/kg. The work therefore explored a nanoparticle-based phytotherapeutic strategy in a preclinical colitis model 42269185Jun.

• A review of innovation in inflammatory bowel disease clinical-trial design discussed umbrella-trial approaches, including the VIBRATO and PIZZICATO trials, which generated insights relevant to both UC and Crohn’s disease. The publication places UC research within a broader effort to improve the efficiency and interpretability of trials evaluating emerging therapies 42285045Jun.

• Shenling Baizhu Powder was examined in patients or experimental contexts described as UC with “spleen deficiency and dampness stagnation” (UC-SDDS). The investigation integrated serum pharmacochemistry, metabolomics, and network pharmacology to identify potentially active components and therapeutic mechanisms. This approach represents a traditional-medicine pharmacology framework that links chemical constituents with biological targets and metabolic pathways 42089391May.

• Real-world data from the Latium Net evaluated the effectiveness and safety of mirikizumab in patients with UC in routine clinical practice. Mirikizumab is represented in the recent literature as an interleukin-23-pathway treatment, complementing studies of other targeted immune therapies and real-world assessments of treatment performance outside controlled trials 42086294May.

• A multiomic analysis of guselkumab induction therapy evaluated cellular and molecular changes in patients with moderately to severely active UC from the QUASAR phase IIb induction study. The study’s design linked clinical treatment with comprehensive molecular characterisation, extending the prominent recent research theme of guselkumab in inflammatory bowel disease 41871904Mar. Together with the clinical-trial-design literature, it illustrates the increasing use of multiomic and platform-based approaches alongside conventional measures of clinical remission.

• Across these publications, UC research is organised around three connected biological priorities: targeted regulation of inflammatory signaling, polysaccharide- and phytochemical-mediated immunomodulation, and restoration of microbiota–epithelial barrier function. Experimental studies involving DSS, macrophages, tight junction proteins, NF-κB, COX-2, and inflammatory cytokines address mechanisms of mucosal injury, whereas clinical studies of duvakitug, mirikizumab, and guselkumab focus on translating pathway-specific interventions into treatment for active disease.